Management of Treatment-Experienced Patients With HIV
Summary
- Two agents are approved for use in combination with other ARV agents in heavily treatment–experienced patients with multidrug resistance who are experiencing failure of their current ART regimen
- Ibalizumab-uiyk: postattachment inhibitor approved by the FDA in 2018
- Fostemsavir: attachment inhibitor approved by the FDA in 2020
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content